Cellebrite DI (CLBT) AI Stock Analysis

• Market Cap: $4.56B
• Dividend Yield: N/A
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): 61.5
• Beta (1Y): 0.77
• Revenue Growth: 18.37%
• EPS Growth: N/A
• Country: US
• Employees: 1,167
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Infrastructure
• EPS (TTM): 0.08
• Shares Outstanding: 239,470,060
• 10 Day Avg. Volume: 1,070,655
• 30 Day Avg. Volume: 1,340,024
• PEG Ratio: -0.08
• Price to Book (P/B): 13.73
• Price to Sales (P/S): 11.50
• P/FCF Ratio: 37.96
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 9.04
• Enterprise Value/Gross Profit: 10.77
• Enterprise Value/Ebitda: 53.30
• 1Y Price Target: $24.20
• Price Target Upside: 28.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 0.35
• Revenue Forecast (FY): $472.81M

• Rating: 66 Neutral
• Price Target: $21.00 ▲(11.58% Upside)

Cellebrite DI's overall stock score is driven by strong earnings call results, highlighting growth in ARR and subscription revenue, and strategic advancements in cloud and SaaS offerings. However, financial performance is hindered by profitability challenges and a high P/E ratio, indicating potential overvaluation. Technical indicators suggest mixed momentum, with the stock trading above key moving averages but showing signs of potential bearishness. The company is well-positioned for future growth, but needs to address profitability and valuation concerns.

Positive Factors

Revenue Growth

The 18% revenue growth reflects strong demand and effective market strategies, indicating robust business expansion and market penetration.

ARR and Subscription Growth

The growth in ARR and subscription revenue underscores a successful transition to a recurring revenue model, enhancing financial predictability and stability.

Cloud and SaaS Expansion

Rapid growth in cloud and SaaS offerings positions Cellebrite for sustained competitive advantage in the digital intelligence market.

Negative Factors

Profitability Challenges

Profitability challenges with negative net margins indicate operational inefficiencies that could hinder long-term financial health.

Free Cash Flow Decline

A decline in free cash flow growth suggests potential cash management issues, which could impact investment capacity and financial flexibility.

US Federal Segment Challenges

Ongoing challenges in the US Federal segment could limit growth opportunities and affect revenue from a key market sector.

Cellebrite DI Business Overview & Revenue Model

Company Description

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.

How the Company Makes Money

Cellebrite generates revenue primarily through the sale of its software and hardware products, including digital extraction devices and analytics tools. The company employs a subscription model for its software services, which provides ongoing revenue through annual licenses and renewals. Additionally, Cellebrite benefits from training and support services offered to its clients, which further contribute to its revenue streams. Key partnerships with government agencies, law enforcement bodies, and enterprises enhance its market presence, while the increasing demand for digital forensics solutions in various sectors, including cybersecurity, also drives its earnings.

Cellebrite DI Financial Statement Overview

Summary

Cellebrite DI demonstrates strong operational efficiency with high gross margins and low leverage, but faces profitability challenges with negative net margins and return on equity. Cash flow management shows mixed results, with strong cash conversion but declining free cash flow growth. The company is positioned for stability with cautious debt management, yet needs to address profitability to enhance financial health.

Income Statement

Cellebrite DI shows a strong gross profit margin of over 84% in TTM, indicating efficient cost management. However, the net profit margin is negative, reflecting challenges in achieving profitability. Revenue growth is modest at 4.39% in TTM, suggesting steady but slow expansion. The EBIT and EBITDA margins are healthy, supporting operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.0547 in TTM, indicating conservative leverage and financial stability. However, the negative return on equity suggests inefficiencies in generating returns for shareholders. The equity ratio is not provided, but the overall balance sheet reflects a cautious approach to debt management.

Cash Flow

Cellebrite DI's free cash flow growth is negative in TTM, indicating potential cash flow challenges. The operating cash flow to net income ratio is over 0.5, showing decent cash generation relative to net income. The free cash flow to net income ratio is strong, suggesting effective cash conversion despite profitability issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	455.90M	401.20M	325.11M	270.65M	246.25M	194.91M
Gross Profit	382.80M	338.61M	271.88M	219.91M	203.69M	157.03M
EBITDA	77.36M	67.51M	-64.80M	130.10M	89.47M	17.28M
Net Income	76.33M	-283.01M	-81.10M	120.81M	71.40M	5.78M
Balance Sheet
Total Assets	834.32M	690.57M	532.88M	403.29M	339.78M	364.39M
Cash, Cash Equivalents and Short-Term Investments	525.71M	447.22M	302.92M	183.62M	181.56M	237.64M
Total Debt	21.44M	10.97M	14.13M	15.36M	0.00	0.00
Total Liabilities	386.63M	354.55M	498.67M	329.43M	413.13M	300.58M
Stockholders Equity	447.69M	336.02M	34.21M	73.86M	-73.35M	63.80M
Cash Flow
Free Cash Flow	139.11M	121.56M	94.14M	11.49M	27.94M	60.33M
Operating Cash Flow	152.70M	132.17M	102.06M	20.58M	36.05M	66.51M
Investing Cash Flow	-38.09M	-149.47M	-22.54M	-91.23M	45.23M	-6.45M
Financing Cash Flow	29.44M	20.65M	21.77M	13.97M	-68.40M	-8.59M

Cellebrite DI Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Positive. The current price of 18.82 is above the 20-day moving average (MA) of 17.83, above the 50-day MA of 17.80, and above the 200-day MA of 17.23, indicating a bullish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 61.70 is Neutral, neither overbought nor oversold. The STOCH value of 89.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLBT.

Cellebrite DI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EVTC	71 Outperform	$1.80B	13.19	25.05%	0.67%	9.67%	75.67%
CLBT	66 Neutral	$4.56B	61.52	20.46%	―	18.37%	―
RDWR	65 Neutral	$1.05B	63.38	5.09%	―	10.40%	―
TUYA	65 Neutral	$1.34B	27.76	4.87%	4.64%	13.36%	―
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
TENB	61 Neutral	$3.20B	―	-8.95%	―	11.05%	45.23%
VRNS	48 Neutral	$3.92B	―	-22.17%	―	11.37%	-34.44%

Cellebrite DI Corporate Events

Cellebrite Completes Acquisition of Corellium, Enhancing Digital Investigation Platform

On December 1, 2025, Cellebrite DI Ltd. completed its acquisition of Corellium, a leader in Arm-based virtualization software, significantly enhancing its digital investigation capabilities. This acquisition strengthens Cellebrite’s market position by integrating Corellium’s virtualization technology, which enhances digital forensics, investigations, analytics, and intelligence. The merger is expected to benefit a wide range of customers, including defense and intelligence sectors, by providing advanced virtualization for secure mobile application development and operational testing. The acquisition was completed with an enterprise value of $170 million, with additional performance-based payments possible. The Committee on Foreign Investment in the United States has permitted the acquisition to close, pending formal clearance.

Cellebrite Reports Strong Q3 2025 Financial Results with 18% Revenue Growth

On November 12, 2025, Cellebrite announced its third-quarter financial results, highlighting a revenue increase of 18% to $126 million and an ARR growth of 19% to $439.8 million. The company reported a net income of $20.2 million, with a non-GAAP net income of $36.9 million and an adjusted EBITDA of $37.7 million. Cellebrite’s performance reflects strong demand, particularly in the U.S. Federal sector, and the company is optimistic about future growth, driven by product development and strategic acquisitions. Recent innovations include the Autumn 2025 Release, which introduced new capabilities to their Digital Investigation Platform, and the appointment of Holly Windham as General Counsel and Chief Compliance Officer.

Cellebrite DI Shareholders Approve Proposals at Annual Meeting

On September 19, 2025, Cellebrite DI Ltd. held its annual general meeting where shareholders approved all proposals presented, with approximately 76.82% of the ordinary shares represented. This approval signifies strong shareholder support and could enhance the company’s strategic initiatives and governance, potentially impacting its market positioning positively.